[1] Iezadi S, Gholipour K, Azami-Aghdash S, Ghiasi A, Rezapour A, Pourasghari H, et al. Effectiveness of non-pharmaceutical public health interventions against COVID-19: a systematic review and meta-analysis. PLoS One 2021;16(11):e0260371. https://doi.org/10.1371/journal.pone.0260371.
[2] Cheng XQ, Hu JL, Luo L, Zhao ZY, Zhang N, Hannah MN, et al. Impact of interventions on the incidence of natural focal diseases during the outbreak of COVID-19 in Jiangsu Province, China. Parasit Vectors 2021;14(1):483. https://doi.org/10.1186/s13071-021-04986-x.
[3] Xiao JP, Dai JY, Hu JX, Liu T, Gong DX, Li X, et al. Co-benefits of nonpharmaceutical intervention against COVID-19 on infectious diseases in China: a large population-based observational study. Lancet Reg Health West Pac 2021;17:100282. https://doi.org/10.1016/j.lanwpc.2021.100282.
[4] Cross M, Ng SK, Scuffham P. Trading health for wealth: the effect of COVID-19 response stringency. Int J Environ Res Public Health 2020;17(23):8725. https://doi.org/10.3390/ijerph17238725.
[5] Perone G. Comparison of ARIMA, ETS, NNAR, TBATS and hybrid models to forecast the second wave of COVID-19 hospitalizations in Italy. Eur J Health Econ 2022;23(6):917 − 40. https://doi.org/10.1007/s10198-021-01347-4.
[6] Zhang YY, Tang S, Yu G. An interpretable hybrid predictive model of COVID-19 cases using autoregressive model and LSTM. Sci Rep 2023;13(1):6708. https://doi.org/10.1038/s41598-023-33685-z.
[7] Abbasi J. “This is our COVID”—what physicians need to know about the pediatric RSV surge. JAMA 2022;328(21):2096 − 8. https://doi.org/10.1001/jama.2022.21638.
[8] Ghaznavi C, Tanoue Y, Kawashima T, Eguchi A, Yoneoka D, Sakamoto H, et al. Recent changes in the reporting of STIs in Japan during the COVID-19 pandemic. Sex Transm Infect 2023;99(2):124 − 7. https://doi.org/10.1136/sextrans-2021-055378.
[9] Oh KB, Doherty TM, Vetter V, Bonanni P. Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm? Expert Rev Vaccines 2022;21(11):1541-53. http://dx.doi.org/10.1080/14760584.2022.2117693.
[10] Feldman AG, O'Leary ST, Danziger-Isakov L. The risk of resurgence in vaccine-preventable infections due to coronavirus disease 2019-related gaps in immunization. Clin Infect Dis 2021;73(10):1920 − 3. https://doi.org/10.1093/cid/ciab127.
[11] Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health 2021;5(12):e44 − 5. https://doi.org/10.1016/s2352-4642(21)00333-3.
[12] Pan QC, Chen XH, Yu YS, Zang GQ, Tang ZH. The outbreak of seasonal influenza after the COVID-19 pandemic in China: unraveling the “Immunity debt”. Infect Dis Now 2024;54(1):104834. https://doi.org/10.1016/j.idnow.2023.104834.
[13] Govender M, Hopkins FR, Göransson R, Svanberg C, Shankar EM, Hjorth M, et al. T cell perturbations persist for at least 6 months following hospitalization for COVID-19. Front Immunol 2022;13:931039. https://doi.org/10.3389/fimmu.2022.931039.
[14] Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022;23(2):210 − 6. https://doi.org/10.1038/s41590-021-01113-x.
Baidu
map